{"disease":{"id":"oral-cavity-carcinoma","name":"oral cavity carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00867464","title":"Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8670,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03488095","title":"Behavior Changing Intervention for Smokeless Tobacco and Betel Quid Use in Adolescents","phase":"NA","overall_status":"COMPLETED","enrollment_count":2200,"lead_sponsor_name":"Dow University of Health Sciences","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04333537","title":"Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":686,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT01810913","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":613,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01473784","title":"Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03942380","title":"Cell-free Tumor DNA in Head and Neck Cancer Patients","phase":"NA","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Christian von Buchwald","has_results":false},{"nct_id":"NCT07441681","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":454,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT05063552","title":"Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":430,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT00588770","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":403,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06798922","title":"Flap Sparing in Postoperative Radiotherapy of Oral Cavity Cancers","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":348,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT05721755","title":"Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":290,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT06947668","title":"Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT02923258","title":"Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":224,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT03258554","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":196,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02734537","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":189,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT04671667","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03917524","title":"Feasibility of CTCs Isolation for Transcriptomes and Genome Wide Associated Analysis in Post-OP High Risk OSCC Patients.","phase":"","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT07195734","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05075980","title":"Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05973656","title":"Role of Acetaldehyde in the Development of Oral Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT06589804","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":158,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT01552434","title":"Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":155,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05136196","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04725396","title":"Study Comparing Fibula Free-flap MR With or Without PVP in Patients With OOPC","phase":"NA","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT02245100","title":"Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":130,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":false},{"nct_id":"NCT01064479","title":"Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04870762","title":"Customized 3D Printed Oral Stents During Head and Neck Radiotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":119,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06662058","title":"Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation","phase":"NA","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT05950737","title":"Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience","phase":"NA","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Tata Memorial Hospital","has_results":false},{"nct_id":"NCT03529604","title":"Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"University of Zagreb","has_results":false},{"nct_id":"NCT06532279","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":98,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT03370276","title":"Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":95,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT06259838","title":"Oral Cavity Squamous Cell Carcinoma and Readmission: Rates, Causes, and Risk Factors.","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"Abdulsalam Alqutub","has_results":false},{"nct_id":"NCT03148665","title":"Saliva-based Detection of CD44","phase":"","overall_status":"COMPLETED","enrollment_count":85,"lead_sponsor_name":"Joseph Califano","has_results":false},{"nct_id":"NCT07180901","title":"Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Centre hospitalier de l'Université de Montréal (CHUM)","has_results":false},{"nct_id":"NCT05927220","title":"WORST PATTERN OF INVASION IN ORAL SQUAMOUS CELL CARCINOMA","phase":"","overall_status":"UNKNOWN","enrollment_count":81,"lead_sponsor_name":"Armed Forces Institute of Pathology Rawalpindi","has_results":false},{"nct_id":"NCT03082534","title":"Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of California, San Diego","has_results":false},{"nct_id":"NCT03422536","title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT07209189","title":"Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":false},{"nct_id":"NCT05461430","title":"Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Travera Inc","has_results":false},{"nct_id":"NCT05749042","title":"A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":70,"lead_sponsor_name":"Xin-Hua Xu","has_results":false},{"nct_id":"NCT01469429","title":"Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT01816841","title":"Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care","phase":"NA","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT02790853","title":"Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":63,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05172258","title":"Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":52,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07121595","title":"Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT01847326","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT00494182","title":"Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}